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Available online 19 October 2016The clinical signiﬁcance of long noncoding RNAs (lncRNAs) in colorectal cancer (CRC) remains largely unex-
plored. Here, we analyzed a large panel of lncRNA candidateswith The Cancer GenomeAtlas (TCGA) CRC dataset,
and identiﬁedH19 as themost signiﬁcant lncRNA associatedwith CRCpatient survival.We further validated such
association in two independent CRC cohorts. H19 silencing blocked G1-S transition, reduced cell proliferation,
and inhibited cell migration. We proﬁled gene expression changes to gain mechanism insight of H19 function.
Transcriptome data analysis revealed not only previously identiﬁed mechanisms such as Let-7 regulation by
H19, but also RB1-E2F1 function and β-catenin activity as essential upstream regulators mediating H19 function.
Our experimental data showed thatH19 affects phosphorylation of RB1 protein by regulating gene expression of
CDK4 and CCND1. We further demonstrated that reduced CDK8 expression underlies changes of β-catenin activ-
ity, and identiﬁed thatH19 interacts withmacroH2A, an essential regulator of CDK8 gene transcription. However,
the relevance of H19-macroH2A interaction in CDK8 regulation remains to be experimentally determined. We
further explored the clinical relevance of abovemechanisms in clinical samples, and showed that combined anal-
ysis of H19 with its targets improved prognostic value of H19 in CRC.








Colorectal cancer (CRC) remains themost frequently diagnosed can-
cer, and a leading cause of cancer-relatedmortality worldwide (Torre etherapeutics, The University of
alin@mdanderson.org
. This is an open access article underal., 2015). In the United States, it is estimated that 132,700 new cases
and 49,700 deaths occur in 2015 (Siegel et al., 2015). Discovering
novel biomarkers and therapeutic targets is of outmost importance to
improve CRC outcome (Toiyama et al., 2016; Abbasi et al., 2015). The
ENCODE project revealed widespread transcription of long noncoding
RNAs (lncRNAs) that possess at least 200 nucleotides in length but do
not code for proteins (Morris and Mattick, 2014; Derrien et al., 2012).
Accumulating evidence suggests that lncRNAs have essential roles in
cancer initiation and progression, and deregulated lncRNA expression
is found in a variety of cancer types (Ling et al., 2015; Spizzo et al.,
2012; Tsai et al., 2011). However, the clinical relevance of lncRNAs in
CRC remains largely unexplored.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
114 M. Ohtsuka et al. / EBioMedicine 13 (2016) 113–124In this study, we analyzed The Cancer Genome Atlas (TCGA) CRC
dataset (Cancer Genome Atlas Network, 2012) for clinical relevance of
lncRNA expression, and identiﬁed H19 as the lncRNA most signiﬁcantly
associatedwith survival. As oneof theﬁrst imprinted genes to bediscov-
ered,H19 is exclusively transcribed from thematernally inherited allele,
and plays key role in embryonic development (Monnier et al., 2013).
Deregulated expression of H19 has been reported in diverse humanma-
lignancies (Raveh et al., 2015). Studies on H19 function in cancer show
both oncogenic and tumor suppressive effects (Medrzycki et al., 2014;
Barsyte-Lovejoy et al., 2006; Hao et al., 1993; Juan et al., 2000). The re-
ported H19 activities are diverse, including interaction with epigenetic
regulators (Monnier et al., 2013; Giovarelli et al., 2014; Zhou et al.,
2015; Luo et al., 2013), regulation of microRNAs as competing endoge-
nous RNA (ceRNA) (Yan et al., 2015; Imig et al., 2015; Kallen et al.,
2013; Liang et al., 2015), or production of miR-675 as a primary tran-
script (Keniry et al., 2012; Venkatraman et al., 2013; Zhu et al., 2014;
Shi et al., 2014; Tsang et al., 2010).
We performed functional studies examiningH19 activity andmech-
anism in CRC.With an unbiased approach to analyze essential networks
mediatingH19 function, we found thatH19 binds to the tumor suppres-
sor retinoblastoma 1 (RB1), and affects the RB-E2F signaling that con-
trols G1-S transition (Polager and Ginsberg, 2009). H19 also regulates
transcription of cyclin-dependent kinase 8 (CDK8), an oncogenic driver
in CRC, and consequently affects β-catenin activity (Firestein et al.,
2008).Weﬁnally validated the clinical relevance and explored theprog-
nostic value of these ﬁndings.
2. Materials & Methods
2.1. Patient Samples
For the TCGAdataset,we obtained andanalyzed gene expression and
clinical data from the Cancer Genome Atlas Project (TCGA; http://tcga-
data.nci.nih.gov/) for CRC patients containing a total of 534 CRC tumor
samples. We used two additional CRC cohorts including 295 cases for
validation. Cohort 2 comprises 178 CRC samples obtained from the
Mie University, Mie, Japan. Cohort 3 contains 117 colon cancer samples
obtained from the Masaryk Memorial Cancer Institute, Czech Republic.
The clinicopathological features of CRC cases are detailed in Table S1.
Tissue samples were obtained from fresh surgical specimens frozen in
liquid nitrogen and stored at −80 °C. All the samples were obtained
with the patients' informed consent and were histologically conﬁrmed.
The Institutional research and ethics committee approved this study.
2.2. RNA Immunoprecipitation (RIP)
We used the Magna RIP Kit (Millipore) according to the
manufacturer's protocol. Cells were prepared in RIP lysis buffer, and
RNA-protein complexeswere immunoprecipitated using corresponding
antibodies. RNA was puriﬁed using phenol:chloroform:isoamyl alcohol
and treated with Dnase to remove genomic DNA, followed by reverse
transcription-PCR or real-time PCR analysis. Control ampliﬁcation was
carried out on input RNA before immunoprecipitation.
2.3. Chromatin Immunoprecipitation (ChIP)
We used the EZ ChIP Kit (Millipore) according to the manufacturer's
protocol. Chromatin was prepared following crosslinking with formal-
dehyde solution. DNA was sheared to size of 200–700 bp by sonication.
The samples were pre-cleared with agarose beads and subsequently
immunoprecipitated using 5 μg of antibodies.
2.4. Affymetrix HTA 2.0 Array
We used Affymetrix Human Transcriptome Array 2.0 for genetic
changes after knocking down H19, CTNNB1 and CDK8. Five hundrednanograms total RNA of each cell line (in duplicate) was provided to
the Sequencing & Non-coding RNA Program at M.D. Anderson Cancer
Center for performing the microarray. Raw data was extracted with
console Affymetrix® Transcriptome Analysis Console (TAC) Software.
Comprehensive function and pathway, including upstream regulator
prediction, were performed by Ingenuity Pathway Analysis (IPA)
(Qiagen). The microarray data was deposited in Gene Expression
Omnibus (GEO) database (accession numbers: GSE87431).2.5. Statistical Analysis
We analyzed the association of gene expression or other clinical pa-
rameters (sex, age, tumor location, tumor stage) with survival using a
Cox proportional hazard model. In the multivariable regression model,
only the factors that were statistically signiﬁcant in univariable analyses
were included. After determining the cut-off value that allowsmost sig-
niﬁcant split with log-rank test in the TCGA dataset, we used the same
cut-off value to generate Kaplan-Meier plots for all cohorts. The
Spearman's rank correlation was applied for the strength of association
between tested genes. The differences between groups were analyzed
using 2-way ANOVA analysis, t-test, or nonparametric test, with the
GraphPad software. Graphics represent the mean± standard deviation
from at least two independent experiments repeated in triplicate, un-
less otherwise stated. Statistical signiﬁcance was considered if P b 0.05.
Additional methods, including Cell Culture, RNA interference exper-
iments, Proliferation Assay, Cell Scratch Assay, Cell-Cycle Assay, Click-iT
EdU Assay, Reverse Transcription Quantitative RT-PCR Analysis, West-
ern Blot, Plasmid and Virus Generation, and Northern Blot are available
in Supplemental Experimental Procedures. Reagent, primer, and anti-
body information is available in Table S3–5.3. Results
3.1. H19 Is an Independent Predictor of CRC Survival
Weanalyzed 534 patients from the TCGACRC dataset for a panel of 84
cancer-related lncRNAs (listed on the QIAGEN Human Cancer
PathwayFinder RT2 lncRNA PCR Array). We excluded lncRNAs that were
detectable in less than half of the samples, and obtained expression data
for 37 lncRNAs. Detailed clinical parameters were available for 483 of
these CRC cases (Table S1). The TCGA analysis revealed that high H19
levels, highMIR31HG levels, and low PRNCR1 levels were signiﬁcantly as-
sociated with shorter overall survival (OS), and High H19, high BLACAT1,
lowMIR155HG, and low PRNCR1 correlated with shorter disease free sur-
vival (DFS), respectively (Fig. 1a andb). As themost signiﬁcant lncRNAas-
sociated with OS (P = 0.0005), H19 does not correlate with the status of
microsatellite stability (Fig. S1a), but shows steady increase (P= 0.0095)
as tumor stage advances (Fig. 1c). Remarkably, the association of H19
with survival was independent of tumor stages [Hazard ratio (HR) 1.11,
95% conﬁdence interval (CI95%) 1.03–1.21, P = 0.011 for OS; and HR
1.11, CI95% 1.01–1.21, P = 0.027 for DFS]. H19-derived microRNA
(Tsang et al., 2010) miR-675-5p was undetectable in TCGA samples,
while miR-675-3p expression correlated with H19 levels (r = 0.65,
P b 0.0001) (Fig. S1b), but was not a predictor for either OS (0.0856) or
DFS (P= 0.1189). In two independent cohorts of 178 CRC cases (cohort
2) and 117 colon cancer cases (cohort 3), respectively, patients with
high H19 expression in primary tumors, measured by quantitative real
time polymerase chain reaction (qRT-PCR), displayed signiﬁcantly
shorter OS (P=0.0026 and P=0.0128 for these two cohorts, respective-
ly) (Fig. 1d, e and f). We could not perform multivariate analysis for the
second cohort because all cases reported as ‘dead’ were from the stage
III–IV group. Multivariate analysis of the third cohort revealed that H19
is an independent prognostic marker (HR 1.28, CI95% 1.08–1.50, P =
0.0034).
Fig. 1.H19 is an independentprognosticmarker for CRC. (a) TCGA analysis of lncRNA and overall survival (OS) or disease free survival (DFS). Top 10 lncRNAs ranked byP value are listed.
In red: P b 0.05. (b) H19 association with CRC OS and DFS in the TCGA cohort. (c) H19 and CRC stage. Data were presented as box-and-whisker plot (10th, 25th, median, 75th and 90th
percentile) and compared with Kruskal-Wallis test. (d, e) H19 and OS in other cohorts. (f) H19 association with OS and DFS in three cohorts. Log-rank test was used for analysis in a
and f. Hazard ratio (HR), Median, 95% conﬁdence interval (CI95%) were indicated. See also Fig. S1.
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We detected a wide range of H19 expression in CRC cell lines: H19
was abundantly expressed in DLD1 and HCT116, but barely detected
in HT29 and SW480 cell lines (Fig. S2a and b). With northern blotting,we detected a band of ~2.5 kb (size of the reported H19 transcript
according to NR_002196.2), with stronger signal in tumors than non-
cancerous mucosae, and high and modest signal in DLD1 and HCT116,
respectively (Fig. S2c). In contrast, miR-675 expression is very low
with Ct value larger than 30 in DLD1 and HCT116 cell lines (Fig. S2b).
Fig. 2. H19 loss of function reduces CRC aggressiveness. (a, b) H19 effect on proliferation, determined with cell counting kit 8 assay. (c, d) H19 effect on DNA synthesis in CRC cells,
determined with Click-iT EdU assay. (e, f) H19 effect on cell migration, determined with cell scratch assay. Typical images on left, and quantiﬁcations on right. Difference was
determined using 2-way ANOVA with GraphPad software. * P b 0.05. See also Fig. S2.
116 M. Ohtsuka et al. / EBioMedicine 13 (2016) 113–124Therefore, we selected these two models for the H19 knock-down ex-
periments, where the inﬂuence of miR-675 would be minimal.
Silencing H19 expression (Fig. S2d) signiﬁcantly reduced cell prolif-
eration, as determined by CCK-8 assay, in both HCT116 (Fig. 2a) and
DLD1 cells (Fig. 2b). Propidium iodide (PI) staining showed a clear re-
duction of cells in the S phase, and accumulation of cells in the G1
phase in both cell lines (Fig. S2e). Concordantly, with Click-iT EdU
assay we identiﬁed a sharp reduction of DNA synthesis in H19 knock-
down cells, with nearly one third and one half drop of EdU-positive
cells with si-H19-1 and si-H19-2, respectively (Fig. 2c and d). Because
of the association of H19with tumor stage (Fig. 1c), we tested the effect
of H19 on cell motility using the scratch assay. To avoid the interference
of cell proliferation, we treated cells with mitomycin C prior to thisassay. H19 knockdown caused a noticeable reduction of cancer cell
migration, in a manner dependent on silencing effect, in both HCT116
(Fig. 2e) and DLD1 (Fig. 2f) cells. Together, these cellular functional
studies clearly showed that H19 plays essential oncogenic role in CRC
cells.
3.3. H19 Regulates RB1-E2F1 Activity
We proﬁled global gene expression changes following H19 knock-
down by using gene expression microarray (GEM). Analyzing with Inge-
nuity Pathway Analysis (IPA, Qiagen), we found that cell cycle control of
chromosomal replication ranks as the top canonical pathway signiﬁcantly
affected, consistentwith the observed phenotype (Fig. S3a). IPA predicted
Fig. 3. H19 regulates RB1-E2F signaling. (a) Predicted transcriptional regulators and microRNAs (z-score N 2.5 or b−2.5, respectively), determined with Ingenuity Pathway Analysis of
microarray data (si-H19-2 versus scrambled control). (b) Predicted connection ofmost signiﬁcant upstream regulators. (c) Predicted RB1 network in regulation of G1-S transition. (d)H19
silencing reduces RB1 phosphorylation without affecting the level of unphosphorylated form. (e) H19 silencing reduces the expression levels of CDK4 and cyclin D1. See also Fig. S3.
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as top transcription regulators, ranked by activation z-score, to be func-
tionally inhibited, and CDKN2A, NUPR1, RB1, let-7, RBL1, TP53, SMARCB1,
GMNN, SOX1, E2F6 as regulators to be functionally activated (Fig. 3a). The
prediction of MYC and let-7 is in consensus with reports that H19 antag-
onizes let-7 to regulateMYC (Yan et al., 2015; Kallen et al., 2013). Among
all these, E2F1 is the most signiﬁcant regulator predicted to control 87 of
the 734 mRNAs changed after H19 knockdown (Fig. 3a). The E2F family
includesmultiple transcription factors, where E2F1-3 are cell cycle activa-
tors, and E2F4-8 are cell cycle repressors (Chen et al., 2009). Interestingly,
the negative regulator of E2F signaling, RB1 is predicted to regulate 90
mRNAs and be functionally activated (Fig. 3a). RB1 is functionally con-
nected with most of the predicted regulators, including CDKN2A, TBX2,E2F1, E2F2, E2F3, E2F6, CCND1, and TP53 (Fig. 3b), and is essential in
regulating G1-S transition (Polager and Ginsberg, 2009), by affecting
transcription of genes including CCNE1, CCNE2 and SKP2 (Fig. 3c). Consis-
tently, IPA analysis of HCT116 si-H19-1, DLD1 si-H19-1, and DLD1 si-H19-
2 samples all predicted that E2F transcriptional activity was inhibited
(Fig. S3b, c and d). However, the RNA (Fig. 3a) and protein expression
levels (Fig. S3e and f for protein) of RB1 and E2F1 were not affected by
si-H19 treatment, suggesting a mechanism independent of transcription
and translation. Phosphorylation of RB1 protein is a critical step in disso-
ciation of RB1-E2F1 complex, which leads to E2F1 activation (Dick and
Rubin, 2013). Consistently with above ﬁndings of H19 on E2F1 function,
H19 silencing dramatically reduced RB1 phosphorylation at ser608
(Fig. 3d). Concordantly, H19 silencing reduced both RNA and protein
118 M. Ohtsuka et al. / EBioMedicine 13 (2016) 113–124expression of CDK4 and cyclin D1, two essential upstream factors control-
ling RB1 phosphorylation (Dick and Rubin, 2013) (Fig. 3e). Interestingly,
we detected an interaction of H19with RB1 protein using RNA immuno-
precipitation (RIP) experiments (Fig. S3g): the biological relevance of
such interaction is not clear. Together, these data suggest that H19
regulates RB1-E2F signaling to control cell proliferation.
3.4. H19 Regulates β-Catenin Activity via Modulating CDK8 Expression
Aberrant activation of Wnt signaling is an essential mechanism of
CRC (Anastas and Moon, 2013). The prediction of CTNNB1 (β-catenin)
as upstream regulator (Fig. 3a) prompted us to examine H19 involve-
ment inβ-catenin activity. GEManalysis ofmRNAswith N2 fold changes
(P b 0.05) revealed that almost one fourth of genes regulated by
siCTNNB1 are modulated by si-H19 in the same direction (Fig. 4a and
Fig. S4). We validated the GEM data by qRT-PCR and western blot
with a high concordance: JAG1, IGF1R, and CSRP2 were noticeably
reduced, and CDH1 expression was increased by both H19 siRNAs
(Fig. 4b and c). We selected NOTCH ligand JAG1, themost downregulat-
ed gene in HCT116 cells, to test whether the changes are mediated
through β-catenin. Chromatin immunoprecipitation (ChIP) revealed a
signiﬁcant drop in polymerase II binding to the transcription start site
(TSS) of JAG1 gene (Fig. 4d), and a reduction of β-catenin binding to
TCF-binding element (TBE) (Rodilla et al., 2009) after H19 silencing
(Fig. 4e). NOTCH activity measured with Cignal RBP-Jk reporter assay
was signiﬁcantly reduced in cells treated with H19, CTNNB1 or JAG1
siRNAs (Fig. 4f). Taken together, these results suggest an intrinsic
connection of H19 with β-catenin activity.
We did not ﬁnd signiﬁcant reduction on total or nuclear β-catenin
protein levels by H19 knockdown (Figs. 4b, and c, and S5a). On the
GEM, CDK8, a CRC oncogenic driver that regulates β-catenin activity
(Firestein et al., 2008), ranks as the most regulated gene by si-H19
(reduced 2 fold and 4 fold, in si-H19-1 and si-H19-2 samples, respec-
tively), but not by si-CTNNB1. CDK8 controls mediator-polymerase II
interaction (Allen and Taatjes, 2015; Tsai et al., 2013), and thus CDK8
changes could impair functions of β-catenin and Med1 as predicted
(Fig. 5a). Further supporting this hypothesis, IPA analysis of HCT116
si-H19–1, DLD1 si-H19-1, and DLD1 si-H19-2 samples consistently sug-
gested that functions of β-catenin and Med1 are inhibited (Fig. S5b, c
and d). We validated the effect of H19 on CDK8 expression with qRT-
PCR andwestern blot (Fig. 5b). Additionally, we proﬁled genes changed
N2 fold (P b 0.05) by si-H19-1, si-H19-2, si-CTNNB1, and si-CDK8, and
identiﬁed 8 overlapping genes that were downregulated, and 13
genes that were upregulated (Fig. 5c and d). We validated the microar-
ray ﬁnding by showing a clear reduction of JAG1, CSRP2, and KIAA1199,
and a marked increase of CDH1 and PPIP5K2 (Figs. 4c, 5e, and S5e).
Similar to H19 knockdown, CDK8 siRNA dramatically reduced CRC cell
proliferation (Fig. 5f). CDK8 overexpression partially rescued the
phenotype triggered by H19 knockdown (Fig. 5f). These data together
suggest that CDK8 is a molecular target mediating the oncogenic
function of H19.
3.5. A Mechanistic Link between H19 and CDK8 Expression
Pretreatment of cells with actinomycin D, an inhibitor of DNA
transcription (Siboni et al., 2015), attenuated the H19 effect on CDK8,
suggesting a transcriptional regulation (Fig. 6a). Concordantly, H19
silencing signiﬁcantly reduced polymerase II binding to the CDK8 TSS
(Fig. 6b). The mechanisms underlying CDK8 transcription are not well
documented. We exclude the possibility that CDK8 is regulated by
promoter methylation since CDK8 RNA expression was not induced by
treatment of CRC cells with the de-methylation agent 5-Aza-2′-
deoxycytidine (data not shown). Recent studies revealed that the his-
tone variant macroH2A is a strong repressive regulator of CDK8 expres-
sion (Kapoor et al., 2010; Xu et al., 2015).H19 silencing does not change
the protein expression levels of macroH2A (Fig. S6). However, with RIPexperiment we detected a strong physical association of H19 RNA with
macroH2A protein (Fig. 6c), indicating a potential macroH2A involve-
ment in the regulation of CDK8 transcription by H19. Together with
the fact that H19 is expressed in both cytosol and nucleus (Fig. 6e),
our data provide additional information on H19 regulation network
that controls CRC malignancies (Fig. 6e).
3.6. Clinical Signiﬁcance of H19 and its Molecular Targets in CRC
We support the CDK8-β-cateninmechanism identiﬁed from cell line
models with the TCGA CRC data. CSRP2, one of the 8 overlapping genes
downregulated by si-H19–1, si-H19–2, si-CTNNB1, and si-CDK8 (Fig.
5d), shows positive association with H19 expression in TCGA CRC sam-
ples (n=534, r=0.26, P b 0.0001) (Fig. 7a). Among the 13upregulated
genes (Fig. 5d), GDA (r =−0.18, P b 0.0001), PPIP5K2 (r =−0.15, P =
0.0004), AGPAT9 (r =−0.15, P = 0.0004), and CDH1 (r =−0.15, P=
0.0006) show inverse correlation with H19 expression (Fig. S7a). CSRP2
(HR = 1.51, CI95% 1.17–1.96, P= 0.001762) is associated with shorter
OS (Fig. 7a), while CDH1 level is associated with longer OS (HR = 0.69,
CI95% 0.51–0.93, P= 0.0145) (Fig. S7a). Combined analysis ofH19with
CSRP2 or CDH1 are powerful independent prognostic factors (HR =
2.53, CI95% 1.39–4.61, P = 0.00242 for H19-high/CSRP2-high versus
H19-low/CSRP2-low; HR = 3.96, CI95% 1.85–8.45, P = 0.00039 for
H19-high/CDH1-low versus H19-low/CDH1-high) for OS, comparable
to the prognostic power of stage (HR = 2.66, CI95% 1.45–4.9, P =
0.00169; and HR = 2.56, CI95% 1.43–4.59, P = 0.0015, respectively)
(Figs. 7a and S7a, and Table S2). We found a positive expression associ-
ation betweenH19 and CDK8 in cohort 2 comprising 178 CRC cases (r=
0.25, P = 0.0008), but not in the TCGA CRC dataset (P = 0.1529) (Fig.
S7b and c). Interestingly, in the 138 rectal cancer cases of the TCGA
set, H19 and CDK8 expression levels are also positively correlated
(r = 0.17, P = 0.0308) (Fig. S7d), and the same was conﬁrmed in an
independent analysis of 71 TCGA rectal cancer cases by TANRIC open-
access resource (r = 0.49, P = 0.000017) (Li et al., 2015) (http://ibl.
mdanderson.org/tanric/_design/basic/query.html) (Fig. S7d). Analysis
of the 138 TCGA rectal cancer cases showed that combined analysis of
H19 and CDK8 expression stratiﬁed patients into different risk groups
(P = 0.0185), with the subgroup expressing both high H19 and CDK8
displaying shortest DFS (Fig. S7e).
To gain furthermechanistic insight, we analyzed expression correla-
tion of all protein coding genes with H19 in the TCGA CRC data set and
performed enrichment analysis using Enrichr (http://amp.pharm.
mssm.edu/Enrichr/) (Chen et al., 2013; Kuleshov et al., 2016). Interest-
ingly, CTNNB1 function ranked at top according to the score combining
both p value and z score: 69 out of the 221 genes that show signiﬁcant
inverse association with H19 (r ≤−0.25) in TCGA dataset are inversely
correlated with CTNNB1 function in the previously published Gene
Expression Omnibus (GEO) data (Mokry et al., 2012) (Fig. 7b).We com-
pared the TCGA association data with the si-H19 microarray data, and
identiﬁed 33 genes (r ≤−0.15 in TCGA data, fold ≥2 in array data)
(Fig. 7c) and 42 genes (r ≥ 0.15 in TCGA data, fold ≤−2 in array data)
(Fig. 7d) in common. The overlapping genes showing inverse correla-
tionwithH19 are enriched forWnt target genes (either by TCF7L2 dom-
inant negative or CTNNB1 knockdown) in the single gene perturbation
database (Mokry et al., 2012) (Fig. 7c). With the transcription factor
binding proﬁle database TRANScription FACtor (TRANSFAC) and
JASPAR, E2F1 is predicted as the top transcription factor in regulation
of the overlapping genes showing positive association with H19 (Fig.
7d). Together, these data concordantly support the clinical relevance
of our mechanism ﬁndings with cell models.
4. Discussion
Despite the fact that many lncRNAs are expressed at low levels, H19
expression is highly abundant and readily detected. Echoing a very
recent study reporting H19 association with CRC survival in 83 CRC
Fig. 4. H19 regulates β-catenin activity. (a) Genes regulated by H19 and β-catenin in HCT116 cells deﬁned as “overlapping” genes (for signiﬁcance: http://nemates.org/MA/progs/
overlap_stats.html). (b, c) H19 effect on overlapping genes and CTNNB1. (d) Polymerase II binding to transcription start site (TSS) of JAG1 gene. (e) β-Catenin binding to TCF-binding
site (TBE) upstream of JAG1 gene. Upper: quantiﬁcation by qRT-PCR; lower: PCR gel image. (f) NOTCH luciferase assay. * P b 0.05. See also Fig. S4.
119M. Ohtsuka et al. / EBioMedicine 13 (2016) 113–124cases (Han et al., 2016), our ﬁndings with 778 CRC cases with multiple
cohorts strongly suggest that H19 could be a useful biomarker for CRC
survival. It would be valuable to test further whether H19 levels associ-
ate with therapeutic response, and this may help identify patients that
could beneﬁt from adjuvant chemotherapy (Dalerba et al., 2016).One advantage of our study is that we used an unbiased approach for
mechanism elucidation. With such approach, we discovered not only the
known H19 targets including let-7 andMYC (Kallen et al., 2013), but also
several additional mechanisms underlying the oncogenic activity of H19
in CRC. First,H19 regulates RB1/E2F signaling bymodulatingRB1 function.
Fig. 5.H19 regulates CDK8 transcription levels. (a)Predicted functional change of CTNNB1 andMED1. (b)H19 on CDK8 levels. (c)Venndiagramof overlapping genes regulated N2 fold in
HCT116 cells by siRNAs against each of CTNNB1,H19, and CDK8. (d)Heatmap representation of Log2 transformed fold changes of overlapping genes. (e) CDK8 effect on overlapping genes
in HCT116 cells. (f) CDK8 effect on cell proliferation. The statistical signiﬁcance between groupswas determined using 2-way ANOVA analysiswith GraphPad software. * P b 0.05. See also
Fig. S5.
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Second, CDK8, an oncogenic driver in CRC, is transcriptionally regulated
by H19. Third, we detected signiﬁcant overlap between genes regulated
byH19 and β-catenin. Although H19 effect onWnt signaling has been re-
ported (Luo et al., 2013;Wang et al., 2016; Liang et al., 2016), we showed
a different mechanism, by which H19 regulates CDK8 expression, and
consequently affects β-catenin activity. Accordingly, we speculate that
H19may be speciﬁcally involved in the canonical consensus molecularsubtypes 2 (CMS2) of CRC that shows high Wnt and MYC activity
(Guinney et al., 2015). Importantly, the essential ﬁndings on E2F1 signal-
ing and β-catenin activity are supported by the clinical data analysis.
The regulatory effect of H19 on RB1-E2F1 can be traced to its tran-
scriptional regulation of CDK4 and cyclin D1, two immediate upstream
regulator of RB1 phosphorylation (Dick and Rubin, 2013). This matches
with the array prediction of CDKN2A (p16), an inhibitor of CDK4-cyclin
D1 function, to be functionally upregulated (Dick and Rubin, 2013).
Fig. 6.Mechanistic link betweenH19 and CDK8 expression. (a) CDK8 expression after exposure to siH19 for 12 h as determined by qRT-PCR in presence or absence of actinomycinD. (b)
H19 silencing reduces polymerase II binding of transcription start site of CDK8 by chromatin immunoprecipitation (ChIP) experiments. (c)H19 interacts with macroH2A protein, by RNA
immunoprecipitation (RIP). (d) In situ hybridization showsH19 expression in both nucleus and cytosol of HCT116 cells. (e)A scheme ofH19 action:we provided additional insights ofH19
on Rb-E2F1 signaling and CDK-β-catenin activity. We propose that H19 interacts with macroH2A, and this may consequently lead to de-repression of genes including CDK8, CDK4, and
CCND1. Increased CDK4-cyclin D1 complex phosphorylates Rb to disrupt Rb-E2F1 interaction, leading to E2F1 activation. The increase of CDK8 expression enhances the function of
mediator complex including MED1, and facilitates the gene regulation by β-catenin. These downstream targets could work in a synergistic way of promoting cell proliferation and
increasing cell motility in CRC. See also Fig. S6.
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RB1 is tightly controlled by its interaction partners: for instance, binding
of RB1 by human papillomavirus E7 oncoprotein inactivates the sup-
pressive effect of RB1 on E2F transcription activators by interrupting
RB1-E2F binding in human cervical cancer (Dyson et al., 1989). Howev-
er, the relevance of RB1 interaction with H19 needs to be further
investigated.
CDK8 oncogene is an essential driver of CRC malignancies withmul-
tiple functions (Guinney et al., 2015; Roychowdhury et al., 2011).
Together with its partner cyclin C, MED12, and MED13, CDK8 form a
subcomplex that controls mediator-polymerase II interaction to initiate
gene transcription (Allen and Taatjes, 2015; Tsai et al., 2013). Whether
CDK8 regulates Wnt target genes through this mediator complex is
not clearly addressed. However, studies suggest that CDK8 possiblystabilizes β-catenin interaction with the promoter of Wnt targets to
achieve regulatory control (Firestein et al., 2008). The reported associa-
tion of CDK8 expression with β-catenin activation in 470 CRC samples
reinforced the intrinsic functional connection between CDK8 and β-ca-
tenin (Firestein et al., 2010). In our study, CDK8 reduction offered a
sound explanation for the predicted decrease in β-catenin and MED1
function following H19 knockdown.
As part of the essential transcription machinery, CDK8 is important
in regulating expression of other genes (Allen and Taatjes, 2015; Tsai
et al., 2013). However, regulators of CDK8 transcription are not well de-
ﬁned, except the ﬁndings that the histone variant macroH2A represses
CDK8 expression (Kapoor et al., 2010; Xu et al., 2015). MacroH2A has
emerged as a critical epigenetic regulator of cancer, and aberrant
expression of macroH2A has been observed in many cancer types
Fig. 7. Clinical signiﬁcance ofH19 and itsmolecular targets in CRC. (a) Expression correlation ofH19 and CSRP2, and their associationwith overall survival (OS) in TCGACRC dataset. (b)
Enrichment analysis of genes showing signiﬁcantly inverse expression correlationwithH19 in TCGA CRC dataset. Geneswith spearman's rank correlation coefﬁcient less or equal to−0.25
were analyzed using Enrichr at http://amp.pharm.mssm.edu/Enrichr/. (c) Genes showing inverse correlation with H19 in both TCGA CRC data and microarray data were subject to
enrichment analysis using Enrichr. To maximize the overlapping genes, we used genes with spearman's rank correlation coefﬁcient ≤−0.15 in TCGA dataset, and used the microarray
data of HCT116 si-H19-2. (d) Genes showing positive correlation with H19 in both TCGA data and microarray data were subject to enrichment analysis using Enrichr. To maximize the
overlapping genes, we used genes with spearman's rank correlation coefﬁcient ≥0.15 in TCGA dataset. See also Fig. S7 and Table S2.
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shown to repress transcription of CDK4 and CCND1, as well as CDK8
(Lei et al., 2014; Yang et al., 2015). We speculate that the interaction
of H19 with macroH2A protein could sequester the suppressive effect
of macroH2A on transcription of above genes, and might represent the
initial mechanism of H19 function. Further studies are warranted to
address this critical gene regulation mechanism. We also acknowledge
the limitation of our study with actinomycin D treatment, where weevaluated CDK8 expression at an early time point of 12 h in respect
with the quick drop of CDK8 level in such experiments. Therefore,
althoughwe believe that transcription regulation should at least partial-
ly contribute to the observed CDK8 changes, we cannot rule out the
possibility that H19 regulates degradation of CDK8 RNA, for instance,
by microRNAs.
Our data revealed that CSRP2 and CDH1 are H19 targets with clinical
signiﬁcance in CRC survival. CDH1 is a well-known tumor suppressor,
123M. Ohtsuka et al. / EBioMedicine 13 (2016) 113–124involved in cell migration and metastasis (Luo et al., 2013). Although
H19 was reported to repress CDH1 expression via interaction with
EZH2 (Luo et al., 2013), our ﬁndings of CDH1 regulation by H19, and
by both of H19 targets CDK8 and β-catenin, suggest a different mecha-
nism on CDH1 regulation. CSRP2 is a rarely studied gene (Hoffmann et
al., 2016), and in this study we identiﬁed its clear association with CRC
survival. Interestingly, our unpublished data showed that E2F1 knock-
down also dramatically reduces and increases CSRP2 and CDH1 mRNA
expression, respectively. Regulation of these two genes by both E2F1
and β-catenin may explain why they are robust H19 targets in both
experimental conditions and clinical samples. Addition of CSRP2 or
CDH1 or CDK8with H19 further improves the prognostic value of H19,
indicating that they are downstream targets mediating H19 function.
In conclusion, we demonstrate the clinical and biological signiﬁ-
cance ofH19 in CRC, and discovered theH19 action on RB1-E2F pathway
and CDK8-β-catenin signaling. We conjecture that H19, abundantly
expressed in primary CRC, could be detected in body ﬂuids and devel-
oped into a biomarker for CRC diagnosis or prognosis. The strategies
employed in this study might be useful in identifying other lncRNA
candidates with translational potential.
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